Press release 16 November 2021. Backahill enters into an agreement to sell AB Cernelle. Backahill AB has entered into an agreement to sell all shares in the subsidiary AB Cernelle to the German pharmaceutical group Dermapharm AG. “We have had a long and very interesting time as owners of Cernelle, which has developed very [Read more]
Cernelle enters China. AB Cernelle, in partnership with MeiRui, a leading Chinese pharmaceutical company specialising in urology, has received approval for Shenitong®, which is an herbal medicinal product for the treatment of benign prostate diseases. Both companies are now preparing for the market launch of Shenitong®, with the product expected to be available on [Read more]
Cernelle – a 100% fossil-free companyBiogas instead of natural gas, charging posts for cars, switching to LED lighting and detailed energy measurement. Following several years of concerted effort to reduce its environmental impact, pharmaceutical company Cernelle located outside of Ängelholm, Sweden, is now completely fossil free as regards its process and heating.AB Cernelle has recently [Read more]
COVID-19 and supply of medicines As the coronavirus outbreak continues to evolve globally, Cernelle is implementing the necessary precautions to safeguard the continued supply of our medicines and provide treatment for the people who need our help. Our supply chain remains intact, and we have not experienced any supply disruptions. The health and safety [Read more]
Cernitol introduced to French urologists and pharmacists in Toulouse. Cernitol 47 mg is now available for sale in France. During a scientific seminar held by Cernelle September 10th in Toulouse, Cernitol was introduced successfully to French urologists and pharmacists. The topic at this symposium was “inflammation in the prostate and chronic pelvic pain”, where by [Read more]
Cernitol Novum is launched in France Cernitol Novum is now available in France under the brand name Cernitol 47 mg. Cernelle is expanding internationally by entering a large and promising market. The French have great confidence and long history of using herbal pharmaceuticals. Cernitol is the first drug approved using pollen extract, as a the [Read more]
New facilities to manage ongoing expansionEnd of 2018, Cernelle’s team moved from a traditional to a modern office space and a new laboratory, both about 1000 sqm. Cernelle’s modern and dynamic spaces are designed to increase growth capacity, work effectiveness and communication between co-workers.« We are growing rapidly and therefore needed a larger office space [Read more]
Bronze sponsor at the Swedish National Conference of Urology 2018 Every year, the Swedish Association of Urology organizes a national conference where about 1 000 participants from all over Sweden gather to share urological science and experience. This year Cernelle hosted a Bronze sponsorship at the conference in Umeå, Sweden. Associate Professors Ralph Peeker [Read more]
AB CERNELLE sponsors the Swedish Association of Urology in Gothenburg. Cernitol, a herbal pharmaceutical medicine to treat symptoms caused by benign prostate diseases. Has been more and more recognised in Sweden as an effective and safe alternative to use. During the national conference in Gothenburg organized by the Swedish Association of Urology, AB Cernelle [Read more]
